Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 157

Similar articles for PubMed (Select 23479200)

1.

The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists.

Eckerle Mize DL, Salehi M.

Curr Diab Rep. 2013 Jun;13(3):307-18. doi: 10.1007/s11892-013-0377-9. Review.

PMID:
23479200
2.

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Morales J.

Postgrad Med. 2011 Nov;123(6):189-201. doi: 10.3810/pgm.2011.11.2508. Erratum in: Postgrad Med. 2012 Jan;124(1):177-8.

PMID:
22104467
3.

The future of incretin-based therapy: novel avenues--novel targets.

Ahrén B.

Diabetes Obes Metab. 2011 Oct;13 Suppl 1:158-66. doi: 10.1111/j.1463-1326.2011.01457.x. Review.

PMID:
21824270
4.

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.

Russell S.

Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Review.

PMID:
23263796
5.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. Review.

PMID:
19801361
6.

[DPP-IV inhibitors and GLP-1 analogues].

Zettl H, Steinhilber D.

Pharm Unserer Zeit. 2010 Mar;39(2):108-13. doi: 10.1002/pauz.201000357. Review. German. No abstract available. Erratum in: Pharm Unserer Zeit. 2010 May;39(3):168.

PMID:
20196037
7.

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Deacon CF, Mannucci E, Ahrén B.

Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24. Review.

PMID:
22471248
8.

GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.

Gallwitz B.

Handb Exp Pharmacol. 2011;(203):53-74. doi: 10.1007/978-3-642-17214-4_3. Review.

PMID:
21484567
9.
10.

Newly approved and promising antidiabetic agents.

Combettes M, Kargar C.

Therapie. 2007 Jul-Aug;62(4):293-310. Epub 2007 Nov 6. Review.

PMID:
17983555
11.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Jellinger PS.

Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Review.

PMID:
21293084
12.

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ.

Diabetes Obes Metab. 2011 May;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x. Epub 2011 Jan 5. Review.

PMID:
21208359
13.

Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.

Wick A, Newlin K.

J Am Acad Nurse Pract. 2009 Nov;21 Suppl 1:623-30. Review.

PMID:
19900193
14.

Complementing insulin therapy to achieve glycemic control.

Barnett AH.

Adv Ther. 2013 Jun;30(6):557-76. Review.

PMID:
23797471
15.

Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.

Moore KB, Saudek CD.

Am J Ther. 2008 Sep-Oct;15(5):484-91. doi: 10.1097/MJT.0b013e3180ed42dc. Review.

PMID:
18806525
16.

[The value of incretin based therapies].

Gallwitz B.

Dtsch Med Wochenschr. 2009 May;134(20):1062-6. doi: 10.1055/s-0029-1222570. Epub 2009 May 6. Review. German. No abstract available.

PMID:
19421931
17.

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E.

Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Review.

18.

Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.

Drab SR.

Pharmacotherapy. 2010 Jun;30(6):609-24. doi: 10.1592/phco.30.6.609. Review.

PMID:
20500049
19.

Incretin therapy and its effect on body weight in patients with diabetes.

Lind M.

Prim Care Diabetes. 2012 Oct;6(3):187-91. doi: 10.1016/j.pcd.2012.04.006. Epub 2012 May 19. Review.

PMID:
22613745
20.

Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.

Tibaldi JM.

Adv Ther. 2014 Mar;31(3):289-317. doi: 10.1007/s12325-014-0100-5. Epub 2014 Feb 15. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk